Vaxcyte, Inc.

PCVXNASDAQHealthcare● Active

$46.37

$-0.99(-2.09%)

Market Cap$6.7B

P/E Ratio—

52W High$65

52W Low$29.08

Avg Volume1.4M

Open$47.76

Beta1.24

Free Cash Flow Financials Revenue

Vaxcyte, Inc. (PCVX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PCVX · free cash flow · updated Jun 8, 2026

Core FCF metrics

PCVX · FCF · TTM · margin & CAGR

Free cash flow was −$669.3M for FY2025 (fiscal year ending 2025-12-31), down 40.9% year-over-year

FY2025 Free Cash Flow−$669.3M▼ -40.9% YoY

Trailing 12M (TTM)−$771.7Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PCVX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$655.6M(14M)−$669.3M▼ 40.9%—

FY2024−$452.6M(22M)−$475.1M▼ 30.3%—

FY2023−$296.8M(68M)−$364.7M▼ 106.7%—

FY2022−$170.6M(6M)−$176.4M▼ 37.9%—

FY2021−$121.4M(7M)−$127.9M▼ 167.8%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PCVX · P/FCF · FCF yield · FCF per share

Vaxcyte, Inc. (PCVX) reported negative free cash flow of −$0.67B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PCVX · cash flow statement · operating / investing / financing

For FY2025, Vaxcyte, Inc. generated −$655.6M in operating cash flow and spent 14M in capital expenditures, yielding −$669.3M in free cash flow.

Operating Activities

−$655.6M

Cash from core business operations

2025-12-31

Investing Activities

+$437.4M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$2.0M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$655.6M) − |CapEx| (14M) = FCF (−$669.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PCVX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Vaxcyte, Inc.YOU

PCVX

−$669.3M-40.9%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Vaxcyte, Inc. (PCVX) reported free cash flow of −$669.3M for FY2025 (fiscal year ending 2025-12-31), down 40.9% year-over-year.

Vaxcyte, Inc. has reported negative free cash flow in recent periods, indicating capital expenditures have exceeded operating cash flow. Data available for 9 fiscal years.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PCVX free cash flow · 8 questions

Vaxcyte, Inc. free cash flow was −$669.3M for FY2025, down 40.9% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$771.7M.

PCVX free cash flowPCVX FCFPCVX FCF 2025PCVX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Vaxcyte, Inc. · Vaxcyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026